Quantification of JAK2V617F mutation by next-generation sequencing technology

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 536-537

  Abdelhamid, Emna ^a,b   Figeac, Martin ^c   Renneville, Aline ^b,c,d   Quief, Sabine ^c,d   Villenet, Céline ^c   Boyer, Thomas ^b   Nibourel, Olivier ^b,c,d   Coiteux, Valerie ^b   Cassinat, Bruno ^e   Lippert, Eric ^f   Helevaut, Nathalie ^b,d   Soua, Zohra ^a   Preudhomme, Claude ^b,c,d  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d Institut de Recherche sur le Cancer de Lille   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ASSESSMENT; DILUTION; FEASIBILITY STUDY; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; POLYCYTHEMIA VERA; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; WILD TYPE;

CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84878177197     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23446     Document Type: Letter

References (2)

1. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:285-293.
2. Quintas-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Invest Drugs 2011;20:961-972.